Veritas In Silico Inc. (JP:130A) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Veritas In Silico Inc. has partnered with Liverpool ChiroChem to develop mRNA-targeted small molecule drugs, aiming to create innovative therapeutics for various diseases. This strategic collaboration combines both companies’ platforms to potentially generate groundbreaking drug candidates. The agreement marks a significant step in Veritas In Silico’s growth strategy, although no immediate revenue is expected from this contract.
For further insights into JP:130A stock, check out TipRanks’ Stock Analysis page.